BioXcel Therapeutics, Inc. (BTAI): Entry into a Material Definitive Agreement
BioXcel Therapeutics, Inc. (BTAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 tm2619779d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 TENTH AMENDMENT TO Credit agreement AND guaranty This Tenth Amendment to Credit Agreement and Guaranty (this “ Amendment ”) is made as of July 3, 2026, by and among BIOXCEL THERAPEUTICS, INC., a Delaware corporation (the
How this was made
The 30-second read
Why it matters
The amendment changes covenant math (minimum liquidity) and extends a scheduled payment, which can influence perceived default risk and the urgency of completing an ‘Acceptable Transaction’ by July 31, 2026.
Market read
This is a concrete financing/covenant update with explicit near-term deadlines, making it relevant for credit-risk and event-driven positioning.
What to watch
Traders should focus on the ‘Acceptable Transaction’ requirement (cash payoff vs alternative capital solutions) and the ‘payment in kind’ mechanics, which can affect leverage optics and near-term liquidity perception.
Background
The 8-K discloses a Tenth Amendment to BioXcel’s existing credit agreement and guaranty, including revised minimum liquidity amounts, a deferred payment date, and additional conditions tied to a July 31, 2026 transaction milestone.
Ticker impact
BioXcel entered a Tenth Amendment to its credit agreement, deferring a June 30, 2026 payment to July 31 and resetting minimum liquidity thresholds.
Near-term trading likely hinges on whether the company can meet the July 31, 2026 transaction milestone; otherwise credit terms may worsen sentiment.
The filing is a primary-source 8-K credit agreement amendment with concrete covenant/liquidity and payment-date changes, but it does not disclose the underlying business/financing outcome yet.
Market effects
For biotech/biopharma issuers with debt facilities, covenant/liquidity resets can reinforce a broader ‘financing runway’ risk lens across the sector.
Primarily US small/mid-cap credit-risk sentiment; limited direct regional spillover implied by the filing.
Low—this is company-specific financing documentation rather than a cross-border macro or regulatory shift.
Counterpoint
The deferral and revised minimum liquidity could be routine lender housekeeping rather than a deterioration signal, especially if the company expects an equity raise or asset transaction to close before the milestone.
Key entities
- issuerBioXcel Therapeutics, Inc.
Borrower under the amended credit agreement; subject of the 8-K and covenant/liquidity changes.
- administrative_agentOaktree Fund Administration, LLC
Administrative agent for the lenders under the credit agreement amendment.
